CRISPR/Cas9 Genome Editing in LGMD2A/R1 Patient-Derived Induced Pluripotent Stem and Skeletal Muscle Progenitor Cells

被引:1
|
作者
Mavrommatis, Lampros [1 ,2 ,3 ]
Zaben, Abdul [1 ,2 ]
Kindler, Urs [1 ]
Kienitz, Marie-Cecile [4 ]
Dietz, Julienne [2 ,5 ]
Jeong, Hyun-Woo [6 ]
Boehme, Pierre [7 ]
Brand-Saberi, Beate [1 ]
Vorgerd, Matthias [2 ]
Zaehres, Holm [1 ,3 ]
机构
[1] Ruhr Univ Bochum, Inst Anat, Med Fac, Dept Anat & Mol Embryol, D-44801 Bochum, Germany
[2] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Dept Neurol, Med Fac,Heimer Inst Muscle Res, D-44789 Bochum, Germany
[3] Max Planck Inst Mol Biomed, Dept Cell & Dev Biol, D-48149 Munster, Germany
[4] Ruhr Univ Bochum, Med Fac, Dept Cellular Physiol, D-44801 Bochum, Germany
[5] Witten Herdecke Univ, Fac Hlth, Dept Human Med, Inst Virol & Microbiol, D-58453 Witten, Germany
[6] Max Planck Inst Mol Genet, Sequencing Core Facil, D-48149 Munster, Germany
[7] Ruhr Univ Bochum, LWL Univ Hosp Bochum, Dept Psychiat Psychotherapy & Prevent Med, D-44791 Bochum, Germany
关键词
GIRDLE MUSCULAR-DYSTROPHY; KAPPA-B PATHWAY; IN-VIVO; PIGGYBAC TRANSPOSASE; MYOGENIC PROGENITORS; PROTEOLYTIC ACTIVITY; GENE-EXPRESSION; SATELLITE CELLS; CALPAIN; MUTATIONS;
D O I
10.1155/2023/9246825
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Large numbers of Calpain 3 (CAPN3) mutations cause recessive forms of limb-girdle muscular dystrophy (LGMD2A/LGMDR1) with selective atrophy of the proximal limb muscles. We have generated induced pluripotent stem cells (iPSC) from a patient with two mutations in exon 3 and exon 4 at the calpain 3 locus (W130C, 550delA). Two different strategies to rescue these mutations are devised: (i) on the level of LGMD2A-iPSC, we combined CRISPR/Cas9 genome targeting with a FACS and Tet transactivator-based biallelic selection strategy, which resulted in a new functional chimeric exon 3-4 without the two CAPN3 mutations. (ii) On the level of LGMD2A-iPSC-derived CD82+/Pax7+ myogenic progenitor cells, we demonstrate CRISPR/Cas9 mediated rescue of the highly prevalent exon 4 CAPN3 mutation. The first strategy specifically provides isogenic LGMD2A corrected iPSC for disease modelling, and the second strategy can be further elaborated for potential translational approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9
    Ben Jehuda, Ronen
    Shemer, Yuval
    Binah, Ofer
    STEM CELL REVIEWS AND REPORTS, 2018, 14 (03) : 323 - 336
  • [2] Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9
    Ronen Ben Jehuda
    Yuval Shemer
    Ofer Binah
    Stem Cell Reviews and Reports, 2018, 14 : 323 - 336
  • [3] CRISPR/Cas9 repairs patient-derived stem cells
    不详
    LAB ANIMAL, 2016, 45 (03) : 86 - 86
  • [4] CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells
    Zhang, Yanli
    Sastre, Danuta
    Wang, Feng
    CURRENT STEM CELL RESEARCH & THERAPY, 2018, 13 (04) : 243 - 251
  • [5] Therapeutic genome editing using CRISPR/Cas9 for arrhythmogenic cardiomyopathy induced pluripotent stem cells derived cardiac tissues
    Caspi, O. Oren
    Chrona, S.
    Gepstein, A.
    Shiti, A.
    Huber, I.
    Arbel, G.
    Gepstein, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 3 - 3
  • [6] Genome Editing in Erythroid Progenitor Cells Mediated By Crispr/Cas9
    Li, Hojun
    Shi, Jiahai
    Lodish, Harvey F.
    BLOOD, 2014, 124 (21)
  • [7] A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells
    Geng, Bing-chuan
    Choi, Kyoung-Han
    Wang, Shan-zhi
    Chen, Peng
    Pan, Xiu-di
    Dong, Nian-guo
    Ko, Jae-Kyun
    Zhu, Hua
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (11) : 1427 - 1432
  • [8] A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells
    Bing-chuan Geng
    Kyoung-Han Choi
    Shan-zhi Wang
    Peng Chen
    Xiu-di Pan
    Nian-guo Dong
    Jae-Kyun Ko
    Hua Zhu
    Acta Pharmacologica Sinica, 2020, 41 : 1427 - 1432
  • [9] Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9
    Park, Chul-Yong
    Sung, Jin Jea
    Cho, Sung-Rae
    Kim, Jongwan
    Kim, Dong-Wook
    STEM CELL REPORTS, 2019, 12 (06): : 1242 - 1249
  • [10] CRISPR/Cas9 genome editing in human hematopoietic stem cells
    Rasmus O Bak
    Daniel P Dever
    Matthew H Porteus
    Nature Protocols, 2018, 13 : 358 - 376